Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency by unknown
Nantakomol et al. Malaria Journal 2013, 12:289
http://www.malariajournal.com/content/12/1/289RESEARCH Open AccessEvaluation of the phenotypic test and genetic
analysis in the detection of glucose-6-phosphate
dehydrogenase deficiency
Duangdao Nantakomol1, Rick Paul2, Attakorn Palasuwan1, Nicholas PJ Day3,4, Nicholas J White3,4
and Mallika Imwong5*Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is particularly prevalent in historically
malaria-endemic countries. Although most individuals with G6PD deficiency are asymptomatic, deficiency can result
in acute haemolytic anaemia after exposure to oxidative agents. A reliable test is necessary for diagnosing the
deficiency to prevent an acute haemolytic crisis following, for example, anti-malarial treatment. The aim of this
study was to investigate which method was the best predictor of this disorder.
Methods: The present study investigated four G6PD activity detections (fluorescence spot (FS), methaemoglobin
reduction (MR), biochemical and cytochemical test). These methods accompanied with mutation analysis of blood
samples were taken from 295 apparently healthy individuals with unknown G6PD deficiency status.
Results: Molecular characterization of 295 Thai adults revealed an overall prevalence of 14.2%. The G6PD Viangchan
(871 G>A) was the most common (83.3%), followed by G6PD Mahidol (487G>A) (11.9%), and G6PD Union (1360 C>T)
(4.8%). There were two cases of G6PD deficiency carrying the double mutations of Viangchan (871G > A)-Mahidol
(487G > A) and Viangchan (871G > A)-Union (1360C > T). In comparison, the prevalence of G6PD deficiency was 6.1% by
FS test and 7.1% by MR test. G6PD activity was 11 ± 2.5 IU/gHb in non-deficient females (mean ± SD), and 10.9 ± 0.6
IU/gHb in non-deficient males. The upper and lower limit cut-off points for partial and severe deficiency in adults were
5.7 IU/gHb (60% of the normal mean) and 0.95 IU/gHb (10% of the normal mean), respectively. All hemizygote,
homozygote and double mutations were associated with severe enzyme deficiency (the residual enzyme activity <10%
of the normal mean), whereas only 14.3% of the heterozygote mutations showed severe enzyme deficiency. Based on
the cut-off value <5.7 IU/gHb, the quantitative G6PD assay diagnosed 83% of cases as G6PD-deficient. Using a
cut-off number of negative cell >20% in the cytochemical assay to define G6PD deficiency, the prevalence of
G6PD deficiency was closest to the molecular analysis (12.9% G6PD-deficient) compared to the others
methods.
Conclusion: The cytochemical method is a significant predictor of this disease, while FS and MR test are
recommended for the detection of severe G6PD deficiency in developing countries.
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Glucose-6-phosphate dehydrogenase (G6PD) is a house-
keeping enzyme that catalyzes the first and rate-limiting
step in the pentose phosphate pathway. Its key role in
metabolism is to provide reducing power in the cyto-
plasm in the form of NADPH. This role is particularly
important in red blood cells where NADPH serves as an
electron donor for detoxification of hydrogen peroxide
via reduced glutathione, and its production is crucial for
the protection of cell from oxidative stress [1]. G6PD defi-
ciency is the most common congenital enzyme deficiency
in man, present in over 400 million people worldwide [2].
The human G6PD gene is located on Xq28, therefore full
manifestation of the defective gene is observed in the male
hemizygote and the female homozygote. In the female
heterozygotes, a mixed population of normal and enzyme-
deficient cells can be found [3]. Discrimination between
hemizygously deficient males or homozygously deficient
females and non-deficient individuals, on the basis of the
determination of G6PDH activity in haemolysate, remains
insufficient.
Expression of G6PD activity in heterozygote females is
dependent on the degree of lyonization and of expression
of the abnormal G6PD variant. Although most individuals
with G6PD deficiency are asymptomatic, exposure to oxi-
dant drugs, such as the anti-malarial drug primaquine,
may induce haemolysis [4-6]. The broad geographical dis-
tribution of this defect and high prevalence in developing
countries make it important for many counties to adapt
tests that are simple and inexpensive. Rapidly ascertaining
the G6PD status of a person is desirable when one is con-
sidering use of a drug contra-indicated in patients with
G6PD deficiency. The semi-quantitative fluorescent spot
test (FS test) and methaemoglobin reduction test (MR
test) are widely used for population screening. These
screening tests are considered to be antiquated methods
of qualitative analysis of G6PD with low specificity and
sensitivity [7,8] and as such, many are sceptical about the
reliability of the outcome of the result of the methodology.
Moreover, the semi-quantitative screening test is not reli-
able in detecting partially deficient individuals [9].
A sensitive cytochemical staining method has been de-
veloped for measuring G6PD activity in female heterozy-
gous individuals [10]. Such a cytochemical assay offers a
potentially good tool for discrimination among G6PD
normal and heterozygously, hemizygously, and homozy-
gously G6PD-deficient patients by the analysis of indi-
vidual cells. Advances in molecular technology have
allowed the molecular characterization of G6PD gene in
any population to be carried out with relative ease [11].
However, there exist a large number of genetic muta-
tions that have differing impact on G6PD activity. Previ-
ous studies have established the molecular abnormalities
responsible for G6PD deficiency in several ethnic groupsin Southeast Asia [12-17]. However, there has been no
comparative study where all current G6PD diagnosis
tests, especially phenotypic tests, were used to detect all
cases of G6PD variants most commonly found in
Thailand, including G6PD Viangchan (871G >A), Canton
(1376G > T), Mahidol (487G >A), Kaiping (1388G >A),
and G6PD Union (1360C > T) [16]. Therefore, the aim of
this study was to compare the results of the semi-
quantitative method, the enzymatic assay, the cytochemi-
cal method to a molecular method and identify which
method was the best predictor of this disorder.
Methods
Sample collection
A total of 295 apparently healthy people with unknown
G6PD deficiency status aged 18–50 years were recruited.
There were 67 males and 228 females. All subjects had
no concurrent infection and none had been hospitalized
for at least three months. The research protocol was ap-
proved by the Ethical Review Committee for Research
Involving Human Subjects in Research, Chulalongkorn
University, in accordance with the International Confer-
ence on Harmonization-Good Clinical Practice (ICH-
GCP). After obtaining informed consent, five milliliters
of blood were obtained by venipuncture and placed into
two tubes containing heparin and acid-citrate-dextrose
(ACD), respectively. Blood samples were stored at 4°C
until used. The FS test and MR test were performed on
heparinized blood, whilst the G6PD activity assay (bio-
chemical and cytochemical-based assay) was performed
on ACD blood.
DNA extraction and Identification of G6PD mutations
DNA was extracted from G6PD-deficient blood samples
by using Qiaquick® Blood DNA extraction kit (Qiagen,
Germany) according to manufacturer’s recommenda-
tions. In analysing the DNA, the strategy adopted was to
screen for the five known G6PD variants that have been
previously reported in Thai G6PD-deficient individuals:
G6PD Mahidol 487, G>A; G6PD Viangchan 871, G>A;
G6PD Kaiping 1388, G>A; G6PD Canton 1376, G>T;
G6PD Union 1360, C>T. All were analysed with poly-
merase chain reaction (PCR)-restriction fragment length
polymorphism (RFLP) as previously described [16].
The mutations were assessed in exons 6, 9, 11, 12, 13
for the identification of the less frequent mutations.
Exons were amplified using primer pairs designed using
Primer 3 software [18]. DNA yield was measured using a
Nanodrop device. The PCR product was detected by
electrophoresis using a 2% agarose gel and UV trans-
luminator provided with the gel documentation system
(Bio-Rad, USA). DNA sequencing was carried out ini-
tially in one direction in all exons, using either the for-
ward or the reverse primer. Fluorescence-based cycle
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BigDye Terminator v3.1 cycle sequencing kit (Applied
Biosystems, USA). The labelled products were subjected
to analysis using the ABI Prism 3100 Genetic Analyzer
(Applied Biosystems, USA) in accordance with the man-
ufacturer’s instructions. All mutations and polymor-
phisms were confirmed by both reverse and forward
primers. Sequencing results were analysed using Se-
quence Scanner 1.0 [19].
Methaemoglobin reduction test
The MR test was performed with a minor modification
of Brewer et al. [20]. Heparinized blood samples were
used only if they were not older than 24 hours. The
working reagent was composed of 180 mM sodium ni-
trite and 280 mM dextrose solution dissolved in 0.4 mM
of methylene blue chloride solution. Preparation of incu-
bation tubes: positive control tube: 0.1 ml of the com-
bined sodium nitrite-dextrose reagent was added
without adding methylene blue; negative control tube: 1
ml of whole blood was mixed with 0.1 ml of distilled
water; unknown sample tube: 0.1 ml of the combined
sodium nitrite-dextrose reagent and 0.1 ml of methylene
blue reagent were mixed with 1 ml of whole blood.
These mixtures were mixed gently by inverting each
tube and all tubes were incubated at 37°C for three
hours. After incubation, 0.1 ml aliquot from each of the
three tubes was transferred into preloaded 10 ml of dis-
tilled water in a glass tube. The colour of the unknown
sample tube was compared visually to the colours of the
positive and negative tube and replicates were tested for
each sample. The unknown sample was considered not
deficient if the colour was clear red, identical to that of
the negative control, or deficient if the colour was dark
grey or brown, identical to the positive control.
Fluorescent spot test (FS test)
This technique is based on the visual evaluation of fluor-
escence reduced NADPH when activated by UV light.
The method detects the fluorescence of NADPH, which
is proportional to G6PD activity, under UV light long-
wave (365 nm). The FS test was performed on the hepa-
rinized blood using a commercial kit (R&D Diagnosis,
Holargos, Greece). Ten microlitres of blood was first in-
cubated with 200 μl of the reagent mixture and spotted
onto filter paper. Fluorescence intensity was measured at
the beginning (zero time), 5, 10, and 20 min after incu-
bation of blood with reagent mixture. Fluorescence in-
tensity was classified into two groups: normal activity
(bright fluorescence) and deficiency (no fluorescence).
Biochemical G6PD activity
Blood samples were stored at 4°C and used only if they
were not older than 24 hours. For the quantitativeevaluation of G6PD activity, the G6PD kit from BIOLABO
SA was used. The kit utilizes the chemical reaction and
the NADPH produced is measured at 340 nm. The
method involved an elution stage for the lysis of red cells
and an assay stage that involved incubation with reagents
containing substrate and cofactor NADP, followed by
photometric measurement of the kinetic reaction at 340
nm. The assay was performed according to the manufac-
turer’s instruction and analysed by spectrophotometer
within 1 hour. Briefly, 2 ml of ACD-blood were cen-
trifuged to remove the buffy coat and washed three times
with cold normal saline. These washed red blood cells
(RBCs) were measured for haemoglobin concentration,
and then 200 μl of the washed RBCs was lyzed by adding
2 ml of haemolyzing solution. Lyzed RBCs were cen-
trifuged at 2,500 rpm for 20 min. The haemolysate was
used within 1 hour. The rate of NADPH production was
measured at 340 nm at 37°C for 10 min. The change of
optical density per minute was calculated to determine the
activity of the G6PD enzyme. In this study, the G6PD ac-
tivity was expressed in international units per gram
haemoglobin (IU/gHb) using the following calculation:
G6PDH IU=gHbð Þ ¼ ΔAbs=min 5000ð Þ
Hb g=dlð Þ
Cytochemical assay
In this test, G6PD activity causes staining of individual
RBCs by the reduction of water-soluble, colourless
tetranitro blue tetrasolium, in its dark-coloured formazan
by NADPH [10,21]. Dark-purple granules are present in
RBC that contains G6PD activity, whereas G6PD-deficient
RBC remains unstained. The number of both positive
(RBC with dark-purple) and negative stained cells (RBC
with little or no staining) were counted at least 1,000
RBCs. Two ml of heparinized blood were stored at 4°C
and tested within one week of collection. Cellular G6PD
activity was performed with a minor modification of the
prior study by van Noorden [10,21]. Briefly, 1 ml of whole
blood was added to 9 ml of 180 mM freshly prepared so-
dium nitrite dissolved in 0.9% NaCl and incubated for 5
min at room temperature. After incubation, the sus-
pension was centrifuged for 15 min at 2,500 rpm, and then
75 μl of pack cells were added to 125 μl of a freshly pre-
pared solution of NADP+ in phosphate buffer and incu-
bated for 10 min at room temperature. After incubation,
the suspension was centrifuged under the same conditions
and 2 ml of a freshly prepared solution of 0.025% glutaral-
dehyde in phosphate buffer were added to the packed
cells. The fixation was performed at room temperature
under continuous rotation for 30 min. After incubation,
the reaction was stopped by washing the fixed cells three
times for 3 min with phosphate buffer. The cells were
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suspension was added to 1 ml of the incubation medium
and incubated for 90 min at 46°C in the dark, with con-
stant rotation. Cells were washed three times with the
same buffer and cells were resuspended in 1 ml phosphate
buffer. Finally, cells were analysed for formazan presence
by light microscopy. A person was considered as normal
when <20% negative cells were found and as heterozygous-
deficient when between 20 and 80% of cells were negative.
When >80% negative cells were observed, males were con-
sidered as hemizygously deficient and females as homozy-
gously deficient.Statistical analysis
The efficacy of the screening test was evaluated by deter-
mining the number of true positive, true negative, false
positive, and false negative. To compare the accuracy of
each of the screening tests in its ability to reflect the true
G6PD status, as defined by molecular analysis, the fol-
lowing were calculated: sensitivity, [a/(a + c)]×100; speci-
ficity [d/(b + d)] ×100; negative predictive value [a/(a + b)] ×
100 and positive predictive value [a/(a + b)] ×100, where
a = true positives, b = false positives, c = false negatives,
and d = true negatives. Statistical analyses were carried
out using SPSS 11.0 statistical programs (SPSS Corpor-
ation, Chicago, IL, USA). P <0.05 was considered statisti-
cally significant.Results
Identification of G6PD mutations
At least one G6PD mutation was identified in 42 of the
295 individuals (14.2% prevalence rate). G6PD Viangchan
(871 G>A) was the most common and was detected in 36
of the 42 individuals (83.3%). G6PD Mahidol (487 G>A)
was found in four individuals (11.9%) and G6PD Union
(1360 C>T) was found in two cases (4.8%) (Table 1).
Among the 36 females, G6PD Viangchan was the dom-
inant variant (80.5%), followed by G6PD Mahidol (8.3%),
and G6PD Union (5.6%); there were two cases of double
mutations, Viangchan-Mahidol and Viangchan-Union.
There was one G6PD Viangchan homozygote. The others
G6PD variants were heterozygotes. In the six male G6PD-
deficient individuals, five cases were G6PD Viangchan
(83.3%) and one case of G6PD Mahidol (16.7%).Table 1 G6PD status based on molecular analysis and G6PD en
Viangchan-Mahidol, VCUN; Viangchan-Union, MH; Mahidol. UN
Gender Total Deficient Numbe
VC
Male 67 6 5 (0.35 ± 0.02)
Female 228 36 29 (4.29 ± 3.61)Assessment of phenotypic test for G6PD deficiency by
biochemical method
The biochemically determined G6PD activity in RBCs of
G6PD normal and G6PD-deficient individuals are shown
in Figure 1. In this study, the normal value of RBC
G6PD activity was 11 ± 2.5 IU/gHb for G6PD normal fe-
males and 10.9 ± 0.6 IU/g Hb for G6PD normal males
(Table 2). The reference range for normal G6PD activity
in Thai adult female and male were 8.5-13.5 IU/gHb and
10.3-11.5 IU/gHb, respectively. Differences in mean nor-
mal G6PD activity between male and female Thai adults
was not statistically significant (P = 0.49). In the hemizy-
gous group, enzyme activity was very low ranging from
0 to 0.37 IU/gHb, whereas activity in the heterozygously
G6PD-deficient group ranged between 0.4 and 12.13 IU/
gHb. G6PD activity was significantly lower in the
hemizygously (P < 0.001) and heterozygously deficient
group (P < 0.001) as compared with the G6PD normal
group. There was significant difference in the mean
G6PD activity between heterozygously and hemizygously
deficient groups (P < 0.001). Based on the cut-off value
<5.7 IU/gHb, the quantitative G6PD assay diagnosed
83% (35 of 42) of G6PD-deficient individuals. Therefore,
17% of G6PD-deficient patients were misdiagnosed as
normal.G6PD mutations and enzyme activity in different variants
In the female heterozygous group, the mean (SD) value
of enzyme activity in G6PD Viangchan, G6PD Mahidol,
and G6PD Union were 4.29 (3.61), 3.23 (2.03), and 2.72
(1.10) IU/gHb, respectively. The level of enzyme activity
in G6PD-deficient individuals carrying the double muta-
tions of Viangchan-Mahidol and Viangchan-Union were
lower at 0.4 and 0.83 IU/gHb, respectively. The level of
enzyme activity in homozygous G6PD Viangchan was
0.36 IU/gHb. Differences between groups were highly
significant (P < 0.01). The mean enzyme concentration
of males with the Viangchan variant was significantly
lower at 0.35 ± 0.02 IU/gHb than female heterozygotes.
The upper and lower limit cut-off points for partial defi-
ciency in females were 6.6 IU/gHb (60% of the normal
mean) and 1.1 IU/gHb (10% of the normal mean), respect-
ively. The upper limit for severe deficiency in females was
1.1 IU/gHb. The upper and lower limit cut-off points for
deficiency in males were 6.54 IU/gHb (60% of the normalzyme level among G6PD variants (VC; Viangchan, VCMH;
; Union)
r of cases (x ± SD of G6PD enzyme activity (IU/gHb))
VCMH VCUN MH UN
- - 1 (0) -
1 (0.4) 1 (0.83) 3 (3.23 ± 2.03) 2 (2.72 ± 1.10)
Figure 1 The means and standard errors of G6PD activity in (A) Red blood cells of G6PD normal, hemizygous, homozygous, and
heterozygous G6PD-deficienct subjects (B) G6PD activity stratified by genotype; MH = Mahidol, VC = Viangchan, VCMH = Viangchan-
Mahidol, VCUN = Viangchan-Union, UN = Union (all groups were significantly different *P < 0.001).
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spectively [1,22]. The mean G6PD activity levels in nor-
mal, partial and severe G6PD-deficient groups are shown
in Table 2. All hemizygotes, both with G6PD Viangchan
and Mahidol had severe enzyme deficiency. Only 14.29%
(five of 35) of the heterozygotes had as severe enzyme de-







(10% of mean value)
Upper limit of
severe deficiency
(60% of mean value)
Male 10.9 1.09 6.54
Female 11 1.1 6.6
Total 9.5 0.95 5.7Assessment of phenotypic test for G6PD deficiency by FS
and MR test
Among the apparently healthy 295 Thais adults, 21 indi-
viduals (7.1%) were found to be G6PD-deficient by MR
test and 18 individuals (6.1%) by FS test. All of these
subjects carried at least one of the identified G6PD vari-
ants. The sensitivity and specificity of both screening
tests were assessed with respect to the genetic analysis
(Table 3). The sensitivity of MR test to detect total
G6PD deficiency was 0.5 and the specificity was 0.98.
The sensitivity of FS test to detect total G6PD deficiency
was 0.43 and the specificity was 1. All hemizygote,
homozygote, and double mutant (100% or 9/9) G6PD-
deficient individuals, whose G6PD activity was less than
0.83 IU/gHb, were correctly detected by both FS test
and MR test. There were differences in the number of
cases of G6PD Viangchan-deficient individuals detected
by MR test and those with FS test. FS test detected
G6PD deficiency in only 22% (8/36) of female adults
with G6PD Viangchan mutation, while MR test detected
G6PD deficiency in 42% (15/36). Among female hetero-
zygotes diagnosed to have normal G6PD by the FS test,
the enzyme level was in the range of 6.9 to 14 IU/gHb,
greater than the upper limit (60% of the normal mean
value).Assessment of phenotypic test for G6PD deficiency by
cytochemical analysis
All hemizygotes, homozygotes and double mutants were
correctly identified by the cytochemical method; the
number of negative cells ranged from 95 to 98% (mean
96%). By comparison, the number of negative cells
among female heterozygote and G6PD normal ranged
from 18 to 67% (mean 54%) and 5 to 24% (mean 11%),
respectively. The number of negative cells was signifi-
cantly higher in all deficient groups as compared to
G6PD normal (P <0.001). Additionally, the number of
negative cells in the hemizygous group was significantly
higher than the heterozygous group (P < 0.001).
When using the cytochemical criteria, individuals were
considered as hemizygote and homozygote or severe de-
ficient G6PD enzyme activity when the number of nega-
tive cells was >90%. When <15% negative cells were
found, individuals were considered as normal and as
heterozygous-deficient when between 20 and 80% of
cells were negative. There was little overlap in the num-
ber of negative cells found in heterozygote individuals
and G6PD normal (8.5% or 3/35). Using a cut-off num-
ber of negative cells <20% RBC to define overall G6PD
Table 3 Assessing accuracy of the two screening tests in
the identification of G6PD status
Parameters MR test FS test
True positive 21/42 14/42
True negative 249/253 253/253
False positive 4/253 0/253
False negative 21/42 28/42
Sensitivity 50% 43%
Specificity 98% 100%
Positive predictive value 84% 100%
Negative predictive value 92% 91%
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specific. When the biochemical data were compared
with the cytochemical data of all samples tested, a sig-
nificant correlation was observed (r = 0.89; P <0.01). A
significant correlation was also observed in samples of
heterozygously deficient patients (r = 0.85; P <0.01). This
correlation shows that biochemically determined G6PD
activity correlates with the percentage of positive cells in
heterozygote female subjects, who often have a G6PD
activity within the normal range in the biochemical test.
Discussion
G6PD deficiency is the most common, congenital, en-
zyme deficiency in humans, present in over 400 million
people worldwide [2], and particularly in areas endemic
for malaria. Routine screening for G6PD deficiency by
semi-quantitative methods (FS test and MR test) is car-
ried out in all hospitals in Thailand, but these do not
diagnose G6PD deficiency in heterozygous women reli-
ably. This study compared the results of semi-quantitative
methods, an enzymatic assay and a cytochemical method
to a molecular method to assess which method was the
best predictor of this disease. Molecular characterization
of 295 Thai adult subjects revealed that the G6PD
Viangchan (871 G>A) was the most common (83.3%),
followed by G6PD Mahidol (487 G>A) (11.9%), and G6PD
Union (1360 C>T) (4.8%). There were two cases of G6PD
deficiency carrying the double mutations between
Viangchan (871G >A)-Mahidol (487G >A) and Viangchan
(871G >A)-Union (1360C >T). This finding is in line with
a previous study by Nuchprayoon et al. showing that the
gene frequency of G6PD Viangchan is high among the
Thais [16]. In contrast to a previous study, this study did
not find G6PD Mahidol was the most common G6PD
variant in Thailand [23]; this variant has recently been
shown to be highly prevalent in the Karen group [24]. This
contradictory result may be explained by the different
population studied and the technique used in mutation
analysis. The finding of this report is similar to that ofNuchprayoon et al., who performed a genetic analysis
[16], whereas the Panich et al. study used biochemical
assays to study patients with acute haemolysis [23].
The overall (both male and female) prevalence of
G6PD deficiency in this study was 7.1% using the semi-
quantitative screening test, compared to 11.86% using
the quantitative enzymatic assay, 12.9% using the cyto-
chemical method, and 14.2% in the molecular analysis.
The G6PD activity of 33.3% (14 of 42) of individuals car-
rying a mutation had <10% of the normal mean or se-
vere enzyme deficiency. The remaining 28 cases had
partial enzyme deficiency and all were misdiagnosed as
normal by both the FS and MR tests. For any of the
G6PD-variant groups, there was no hemizygous-
deficient male case with partial enzyme deficiency; all
G6PD-deficient males thus had severe enzyme defi-
ciency. The FS and MR tests correctly diagnosed all
male G6PD deficiency and the female severe deficiency
individuals, who were homozygote double mutants.
However, in the group of heterozygously G6PD-deficient
females, the FS and MR test detected G6PD deficiency
with nearly a 50% reduced success rate as compared to
the molecular analysis. Thus the semi-quantitative
screening test failed to diagnose 50% of G6PD deficiency
and these cases were found to be exclusively females. It
appears that although the semi-quantitative test can
diagnose severe G6PD deficiency, it is not able to
diagnose a substantial proportion of heterozygous
G6PD-deficient individuals, who are nevertheless par-
tially deficient, with G6PD activity ranging from 10 to
60% of normal.
Although genetic analysis provides a robust method of
detecting known G6PD-variants, the technique is cur-
rently not sufficiently developed for routine screening;
not only are there many variants to consider, there are
likely several more that have yet to be identified. The cy-
tochemical assay was a significant predictor of this dis-
ease and should be considered as a candidate to replace
current methods. This study established the normal
range, the mean and the standard deviation for G6PD
activity for Thai adults. The overall means for G6PD-
deficient and normal adults were 2.5 IU/gHb and 9.5
IU/gHb, respectively. It is crucial to determine the 60%
cut-off point for mean normal residual G6PD activity to
diagnose G6PD deficiency and determine the 10 to 60%
range to establish partial deficiency. The partial defi-
ciency ranges for G6PD activity in adult was 0.95-5.7
IU/gHb. The one case of partial deficiency, diagnosed as
deficient by the semi-quantitative screening test, was a
G6PD Viangchan heterozygote whose enzymatic level
was 1.94 IU/gHb (20.4% of normal). It appears that the
semi-quantitative screening test could only detect cases
with the residual RBC enzyme activity lower than a cut-
off point that is lower than 1.94 IU/gHb. The findings in
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normal activity was set as the cut-off point for diagnos-
ing G6PD deficiency [9]. Generally, G6PD deficiency is
accepted when the activity is <1.5 IU/gHb [22]; this cri-
terion may not be suitable for all populations, who may
have different G6PD variants and hence levels of enzyme
activity. The discrepancies on the cut-off value in quan-
titative assays should be defined in each population and
tested.
G6PD deficiency is the most common inherited blood
disorder and developing a standardized, robust method-
ology for population screening is vital for appropriate
patient care. Most individuals with G6PD deficiency are
asymptomatic but exposure to oxidant drugs, such as
the anti-malarial drug primaquine, may induce haemoly-
sis [4-6]. Primaquine is currently the only medication
used for radical cure of P. vivax infection, which is fre-
quently found in Thailand. Patients with G6PD defi-
ciency have an increased susceptibility to hemolysis
when given primaquine [25,26]. This potentially fatal
clinical syndrome can be avoided if patients are tested
for G6PD deficiency, adequately informed before being
treated and placed under surveillance.Conclusion
The classical and perhaps best methods for detection of
G6PD deficiency are the FS test and MR tests, which are
inexpensive qualitative tests that are relatively rapid and
easy to conduct. The biochemical assay is a quantitative
method and is a significant predictor of this disease,
while FS and MR test are recommended for the detec-
tion of severe G6PD deficiency in developing countries.
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